Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2020-09-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
未来三年（2020年-2022年）股东分红回报规划
Regulatory Filings Classification · 95% confidence The document is titled as a "Future Three-Year (2020-2022) Shareholder Dividend Return Plan" issued by the company's board of directors. It details the company's dividend policy, principles, procedures, and conditions for cash and stock dividends over a multi-year period. The content focuses on dividend planning and shareholder returns rather than announcing actual dividend amounts or payment dates. It is a policy or planning document rather than a dividend amount notice or a report containing financial results. The document length is 3511 characters, which is relatively short and does not contain financial statements or earnings data. It is not an announcement of dividend amounts (DIV), nor a report publication announcement (RPA). It fits best as a regulatory filing related to dividend policy and shareholder return planning, which does not fit neatly into other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-09-29 Chinese
关于非公开发行股票摊薄即期回报对公司主要财务指标的影响及公司采取措施的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the impact of a non-public stock issuance on immediate earnings dilution and the measures the company will take to mitigate this dilution. It includes detailed financial assumptions, projections of earnings per share under different scenarios, and commitments from the board, senior management, and controlling shareholders to protect investor interests. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and discusses the rationale, risk warnings, and governance measures related to the capital raising. The content focuses on the impact of a capital financing event (non-public stock issuance) on financial metrics and shareholder returns, along with the company's planned responses. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is over 6,700 characters and contains substantive financial data and analysis, not merely an announcement of a report or a certification. Therefore, the appropriate classification is CAP with high confidence.
2020-09-29 Chinese
2020年度非公开发行A股股票预案
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020年度非公开发行A股股票预案" which translates to "2020 Annual Non-public Issuance of A Shares Stock Proposal". It contains detailed information about a non-public stock issuance plan, including background, purpose, issuance details, pricing, number of shares, use of proceeds, approval procedures, and risk analysis. The document is a comprehensive plan and proposal for a capital raising activity through a non-public stock issuance. It is not a financial report, earnings release, or management discussion. It is clearly an update and announcement related to the company's capital structure and financing activities. Therefore, the document fits best into the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed substantive content about the financing plan, not just an announcement of a report or a brief notice. Hence, it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear focus on a stock issuance plan and fundraising details.
2020-09-29 Chinese
关于JT“Enarodustat”获批日本上市的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a product ('Enarodustat') for market launch in Japan by a partner company (JT). It includes details about the licensing agreement, clinical trial results, and potential impact on the company's business. The document is relatively short (1052 characters) and serves as an informational announcement rather than a detailed financial report or regulatory filing. It does not contain financial statements, management discussion, or voting results. It is not a report publication announcement since it does not mention the release of a report. The content fits best with a Regulatory Filings (RNS) classification as a general regulatory announcement about a significant business development that does not fit other specific categories.
2020-09-28 Chinese
关于董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Mr. Wen Zhongyi, from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the resignation, its effective date, and confirms that the board remains compliant with legal requirements. There is no financial data, no mention of reports or meetings, and the content focuses solely on management changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and the content is specific to a director's resignation, confirming the classification with high confidence.
2020-09-28 Chinese
关于医疗器械临床试验备案的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the clinical trial filing for a medical device product (a drug-eluting peripheral balloon catheter). It includes details about the product, clinical trial approval, and regulatory filing status. The document is short (1180 characters) and serves as an announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial data, management discussion, or detailed report content. It is not an annual report, interim report, earnings release, or any other financial filing. It is a regulatory announcement about clinical trial filing and related information, fitting best under Regulatory Filings (RNS).
2020-09-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.